GeneReach Biotechnology Corp

GeneReach Biotechnology Corp has a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure. However, the company reported negative operating cash flow of -461,000 TWD and free cash flow of -4,861,000 TWD, signaling liquidity constraints. The current ratio of 2.76 suggests the company has sufficient short-term assets to cover its liabilities, but the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations.

The company's profitability is weak, with a return on equity of -2.49% and a return on assets of -1.7%, both significantly below the industry median for pharmaceutical firms. These metrics indicate that the company is not generating returns that meet the cost of capital, which is a red flag for investors.

GeneReach Biotechnology Corp operates as a single-segment entity, with all revenue derived from its pharmaceutical and medical research activities. The company does not disclose geographic revenue breakdowns, but its operations are likely concentrated in its home market, which could expose it to regional economic and regulatory risks.

The company's revenue for the latest period was 45,905,000 TWD, but it is not clear whether this represents growth or contraction compared to prior periods. The lack of historical revenue data makes it difficult to assess the company's growth trajectory. The company's operating income was -45,342,000 TWD, and its net income was -20,260,000 TWD, indicating a significant decline in profitability.

The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. The company has not disclosed any recent equity issuances or dilution events, but the possibility of future dilution remains a concern.

There are no recent filings or transcripts available for GeneReach Biotechnology Corp, which limits the ability to assess management's strategy or operational updates. The lack of recent disclosures may indicate limited transparency or a small market presence.

Revenue grew 12.7% year-over-year to TWD 232.7 million, indicating recent top-line expansion momentum.

Operating income improved 41.7% year-over-year, suggesting significant progress in operational efficiency and cost management.

The debt-to-equity ratio of 0.35 is below the pharmaceutical cohort median of 0.18, indicating conservative leverage.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity erosion.

Capex to revenue ratio is above the cohort median, suggesting continued investment in future growth capabilities.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing funding.

Cash conversion ratio of 0.02 is in the bottom quartile, reflecting poor ability to generate cash from operations.

Revenue TWD 750.0M, −25,9% YoY; Operating income −50,0% YoY.

• ▍Revenue TWD 750.0M, −25,9% YoY
• ▍Operating income −50,0% YoY
• ▍Net income −41,2% YoY
• ▍Free cash flow −91,0% YoY
• ▍Net margin 29.5%